Skip to main content

Table 3 Selected sensitivity analysis

From: Effectiveness of polymyxin B-immobilized fiber column in sepsis: a systematic review

 

No. of studies

No. of patients

Effect size

95% CI

Overall effect

(P value)

Heterogeneity

(P value)

Change in MAP

  

(mm Hg)

   

All

12

275

19

(15, 22)

< 0.001

< 0.001

n > 20

5

175

18

(13, 22)

< 0.001

< 0.001

Pre-PMX MAP < 70

3

41

26

(22, 30)

< 0.001

0.85

Pre-PMX MAP ≥ 70

9

234

16

(13, 18)

< 0.001

0.07

Center duplication

11

268

18

(15, 21)

< 0.001

< 0.001

Change in dopamine/dobutamine dose

 

(μg/kg per minute)

   

Alla

4

96

-1.8

(-3.3, -0.4)

0.01

< 0.001

Pre-PMX MAP <70

1

24

-5.0

(-6.6, -3.4)

< 0.001

N/A

Pre-PMX MAP ≥ 70

3

72

-0.8

(-1.2, -0.4)

< 0.001

0.33

Change in PaO2/FiO2 ratio

  

(Units)

   

Alla

7

151

32

(23, 41)

< 0.001

0.87

Pre-PMX PaO2/FiO2 ratio < 200

2

36

30

(19, 40)

< 0.001

0.62

Pre-PMX PaO2/FiO2 ratio ≥200

5

115

40

(20, 60)

< 0.001

0.84

Change in endotoxin level

  

(pg/ml)

   

All

17

455

-21.2

(-24.9, -17.5)

< 0.001

< 0.001

Excluding MRSA

15

410

-24.1

(-28.0, -20.2)

< 0.001

< 0.001

Pre-PMX endotoxin <30 pg/ml

5

97

-9.8

(-12.1, -7.5)

< 0.001

0.007

Pre-PMX endotoxin ≥30 pg/ml

12

358

-28.2

(-32.3, -24.1)

< 0.001

< 0.001

Pre-PMX endotoxin <40 pg/ml

10

283

-14.9

(-18.7, -11.1)

< 0.001

< 0.001

Pre-PMX endotoxin ≥40 pg/ml

7

172

-37.4

(-41.9, -32.8)

< 0.001

0.25

Center duplication

6

225

-16.4

(-24.0, -8.9)

< 0.001

< 0.001

Mortality

  

Risk ratio

   

All

15

920

0.53

(0.43, 0.65)

< 0.001

0.07

RCT

8

354

0.50

(0.37, 0.68)

< 0.001

0.12

Parallel non-RCT

7

566

0.55

(0.38, 0.81)

0.002

0.07

Excluding MRSA

13

840

0.55

(0.44, 0.69)

< 0.001

0.08

RCT excluding MRSA

6

274

0.55

(0.40, 0.76)

< 0.001

0.2

n > 20

7

722

0.56

(0.46, 0.68)

< 0.001

0.17

APACHE II score < 25

9

713

0.56

(0.43, 0.73)

< 0.001

0.06

APACHE II score ≥ 25

6

207

0.45

(0.30, 0.68)

< 0.001

0.25

28- to 30-day mortality only

9

704

0.54

(0.43, 0.68)

< 0.001

0.12

Center duplication

8

673

0.61

(0.46, 0.82)

0.001

0.03

  1. aFor outcomes of dopamine/dobutamine dose and PaO2/FiO2 ratio, all included studies had a sample size greater than 20. APACHE, Acute Physiology and Chronic Health Evaluation; CI, confidence interval; MAP, mean arterial pressure; MRSA, methicillin-resistant Staphylococcus aureus; N/A, not applicable; PaO2/FiO2, arterial partial pressure of oxygen/fraction of inspired oxygen; PMX, polymyxin B-immobilized fiber column; RCT, randomized controlled trial.
Back to article page

Critical Care

ISSN: 1364-8535